GlassScriptPhysician profile
Robert Lee Giffin
NPI 1376584052
$3,817.73
in general payments reported to CMS, 2019-2025
31 companies · $665 in 2025
The $665 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $637 · 2020: $645 · 2021: $483 · 2022: $442 · 2023: $597 · 2024: $349 · 2025: $665.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,610.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,610.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $834.80 | 2019-2025 | Wegovy, Saxenda, Ozempic |
| Astrazeneca Pharmaceuticals LP | $460.05 | 2020-2025 | Breztri, Farxiga |
| Astellas Pharma US INC | $336.58 | 2023-2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $211.55 | 2022-2023 | |
| Amgen INC. | $179.93 | 2019-2020 | |
| Abbott Laboratories | $174.73 | 2020-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Allergan, INC. | $164.62 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $139.36 | 2019-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $138.37 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $138.00 | 2020-2022 | |
| Phathom Pharmaceuticals, INC. | $129.25 | 2024-2025 | Voquezna |
| Glaxosmithkline, LLC. | $124.77 | 2020-2023 | Shingrix |
| Idorsia Pharmaceuticals US INC | $118.88 | 2023-2024 | Quviviq |
| Lilly USA, LLC | $85.24 | 2020-2025 | Zepbound, Mounjaro, Jardiance |
| Arbor Pharmaceuticals, INC. | $54.56 | 2019-2020 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $48.69 | 2020-2025 | |
| Horizon Therapeutics Plc | $48.06 | 2021-2022 | |
| Abbvie INC. | $46.27 | 2022-2025 | |
| Avanir Pharmaceuticals, INC. | $44.22 | 2022 | |
| Merck Sharp & Dohme LLC | $43.83 | 2019-2024 | Gardasil, Gardasil 9, Capvaxive |
| Stryker Corporation | $42.27 | 2025 | Clottriever Bold Catheter |
| Eisai INC. | $40.57 | 2020 | |
| Lundbeck LLC | $40.20 | 2023-2024 | Vyepti, Rexulti |
| Biohaven Pharmaceutical Holding Company LTD. | $37.47 | 2022 | |
| Sanofi Pasteur INC. | $27.67 | 2025 | |
| Inspire Medical Systems, INC. | $22.56 | 2025 | Inspire |
| Mylan Specialty L.P. | $22.41 | 2024 | Yupelri |
| Exact Sciences Corporation | $16.92 | 2023 | Cologuard Collection Kit |
| Nestle Healthcare Nutrition INC. | $16.55 | 2021 | |
| Esperion Therapeutics, INC. | $15.86 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $13.49 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Giffin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.